Ochre Bio develops genomic medicines that rejuvenate transplanted livers, ultimately with the goal of applying these therapies to treat fatty liver disease (NASH/NAFL) and other metabolic diseases.
Ochre employs spatial sequencing, advanced genomics, and high-throughput screening to identify disease-causing genes, and develops combination therapies which are tested in donor livers kept alive outside of the body. In Jan 2021, Ochre completed the largest genomic atlas of the liver, and is currently progressing multiple GalNAc-siRNA candidates toward the clinic. Their scientific roots can be traced back over 15 years leading liver genomics research, and experience in bringing advanced therapies to market. Privately held, Ochre Bio is situated within the heart of Oxford’s biotech innovation hub.